Dawood Khan1, Srividya Vasu1, R Charlotte Moffett1, Nigel Irwin2, Peter R Flatt1. 1. SAAD Centre for Pharmacy and Diabetes, Ulster University, Coleraine, Northern Ireland, UK. 2. SAAD Centre for Pharmacy and Diabetes, Ulster University, Coleraine, Northern Ireland, UK. Electronic address: n.irwin@ulster.ac.uk.
Abstract
BACKGROUND: In the present study we assessed the impact of neuropeptide Y receptor (NPYR) modulators, neuropeptide Y (NPY) and pancreatic polypeptide (PP), on islet function and beta-cell survival. METHODS: The effects of NPY and PP on beta-cell function were examined in BRIN BD11 and 1.1B4 beta-cells, as well as isolated mouse islets. Involvement of both peptides in pancreatic islet adaptations to streptozotocin and hydrocortisone, as well as effects on beta-cell proliferation and apoptosis was also evaluated. RESULTS: Neither NPY nor PP affected in vivo glucose disposal or insulin secretion in mice. However, both peptides inhibited (p<0.05 to p<0.001) glucose stimulated insulin secretion from rat and human beta-cells. NPY exerted similar insulinostatic effects in isolated mouse islets. NPY and PP inhibited alanine-induced changes in BRIN BD11 cell membrane potential and (Ca2+)i. Streptozotocin treatment decreased and hydrocortisone treatment increased beta-cell mass in mice. In addition, streptozotocin, but not hydrocortisone, increased PP cell area. Streptozotocin also shifted the normal co-localisation of NPY with PP, towards more pronounced co-expression with somatostatin in delta-cells. Both streptozotocin and hydrocortisone increased pancreatic exocrine expression of NPY. More detailed in vitro investigations revealed that NPY, but not PP, augmented (p<0.01) BRIN BD11 beta-cell proliferation. In addition, both peptides exerted protective effects against streptozotocin-induced DNA damage in beta-cells. CONCLUSION: These data emphasise the involvement of PP, and particularly NPY, in the regulation of beta-cell mass and function. GENERAL SIGNIFICANCE: Modulation of PP and NPY signalling is suitable for further evaluation and possible clinical development for the treatment of diabetes.
BACKGROUND: In the present study we assessed the impact of neuropeptide Y receptor (NPYR) modulators, neuropeptide Y (NPY) and pancreatic polypeptide (PP), on islet function and beta-cell survival. METHODS: The effects of NPY and PP on beta-cell function were examined in BRIN BD11 and 1.1B4 beta-cells, as well as isolated mouse islets. Involvement of both peptides in pancreatic islet adaptations to streptozotocin and hydrocortisone, as well as effects on beta-cell proliferation and apoptosis was also evaluated. RESULTS: Neither NPY nor PP affected in vivo glucose disposal or insulin secretion in mice. However, both peptides inhibited (p<0.05 to p<0.001) glucose stimulated insulin secretion from rat and human beta-cells. NPY exerted similar insulinostatic effects in isolated mouse islets. NPY and PP inhibited alanine-induced changes in BRIN BD11 cell membrane potential and (Ca2+)i. Streptozotocin treatment decreased and hydrocortisone treatment increased beta-cell mass in mice. In addition, streptozotocin, but not hydrocortisone, increased PP cell area. Streptozotocin also shifted the normal co-localisation of NPY with PP, towards more pronounced co-expression with somatostatin in delta-cells. Both streptozotocin and hydrocortisone increased pancreatic exocrine expression of NPY. More detailed in vitro investigations revealed that NPY, but not PP, augmented (p<0.01) BRIN BD11 beta-cell proliferation. In addition, both peptides exerted protective effects against streptozotocin-induced DNA damage in beta-cells. CONCLUSION: These data emphasise the involvement of PP, and particularly NPY, in the regulation of beta-cell mass and function. GENERAL SIGNIFICANCE: Modulation of PP and NPY signalling is suitable for further evaluation and possible clinical development for the treatment of diabetes.
Authors: K Jiang; D Chaimov; S N Patel; J-P Liang; S C Wiggins; M M Samojlik; A Rubiano; C S Simmons; C L Stabler Journal: Biomaterials Date: 2018-09-07 Impact factor: 12.479
Authors: Wei Xu; Jun Liang; H F Geng; Jun Lu; Rui Li; X L Wang; Qian Lv; Ying Liu; Jie Wang; X K Liu; Peter M Jones; Zl Sun Journal: Int J Endocrinol Date: 2019-04-11 Impact factor: 3.257
Authors: Patricio Atanes; Inmaculada Ruz-Maldonado; Ross Hawkes; Bo Liu; Min Zhao; Guo Cai Huang; Israa Mohammed Al-Amily; Albert Salehi; Stefan Amisten; Shanta J Persaud Journal: Cell Mol Life Sci Date: 2018-02-17 Impact factor: 9.261
Authors: Dawood Khan; Ryan Kelsey; Rashmi R Maheshwari; Virginia M Stone; Annie Hasib; Fiona N Manderson Koivula; Aoife Watson; Stephen Harkin; Nigel Irwin; James A Shaw; Neville H McClenaghan; Viktória Venglovecz; Attila Ébert; Malin Flodström-Tullberg; Michael G White; Catriona Kelly Journal: Sci Rep Date: 2019-08-02 Impact factor: 4.379
Authors: Anna B Osipovich; Jennifer S Stancill; Jean-Philippe Cartailler; Karrie D Dudek; Mark A Magnuson Journal: Diabetes Date: 2020-04-24 Impact factor: 9.337